Prestige Consumer Healthcare (NYSE:PBH) Stock Price Up 4.9%

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) rose 4.9% during trading on Friday . The company traded as high as $69.30 and last traded at $68.50. Approximately 107,982 shares traded hands during trading, a decline of 55% from the average daily volume of 242,065 shares. The stock had previously closed at $65.28.

Analyst Ratings Changes

PBH has been the topic of a number of analyst reports. DA Davidson raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $65.00 to $93.00 in a research note on Friday. Canaccord Genuity Group reissued a “buy” rating and issued a $80.00 price target on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. Finally, StockNews.com downgraded shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.25.

Prestige Consumer Healthcare Stock Up 6.3 %

The company has a current ratio of 3.20, a quick ratio of 2.02 and a debt-to-equity ratio of 0.68. The company has a market cap of $3.46 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 1.85 and a beta of 0.50. The firm’s fifty day simple moving average is $67.16 and its 200 day simple moving average is $66.34.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.14 by ($0.12). Prestige Consumer Healthcare had a net margin of 18.60% and a return on equity of 13.48%. The company had revenue of $277.00 million during the quarter, compared to analyst estimates of $287.42 million. During the same quarter in the previous year, the company posted $1.07 EPS. The company’s quarterly revenue was down 3.1% on a year-over-year basis. Sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.42 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of PBH. Congress Wealth Management LLC DE raised its position in Prestige Consumer Healthcare by 246.1% during the 4th quarter. Congress Wealth Management LLC DE now owns 114,220 shares of the company’s stock worth $6,993,000 after buying an additional 81,215 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Prestige Consumer Healthcare by 5.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 605,376 shares of the company’s stock worth $37,061,000 after buying an additional 30,288 shares during the last quarter. Congress Asset Management Co. MA raised its position in Prestige Consumer Healthcare by 596.2% during the 4th quarter. Congress Asset Management Co. MA now owns 679,256 shares of the company’s stock worth $41,584,000 after buying an additional 581,685 shares during the last quarter. Truist Financial Corp raised its position in Prestige Consumer Healthcare by 54.1% during the 4th quarter. Truist Financial Corp now owns 6,558 shares of the company’s stock worth $401,000 after buying an additional 2,302 shares during the last quarter. Finally, Norges Bank purchased a new position in Prestige Consumer Healthcare during the 4th quarter worth $27,739,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.